Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter open-label phase I/II study of YL201 in selected advanced solid tumors
CTR20232651Phase 2Active
- Sponsor
- MediLink Therapeutics
- Start
- Oct 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of YL201 in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), Esophageal Squamous Cell Carcinoma (ESCC), metastatic castration-resistant prostate cancer (mCRPC), sponsored by MediLink Therapeutics. Started Oct 2023; status: active.
02
Drugs
YL201
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)nasopharyngeal carcinoma (NPC)Esophageal Squamous Cell Carcinoma (ESCC)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20232651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232651.